An effective medical education programme to enable shared physician-patient decision-making in the treatment of progressive colorectal cancer (3rd-line treatment of mCRC).


An insightful video and e-learning to demonstrate best practice, as well as what to avoid, in order to achieve a shared decision-making interaction with the aim of improving patient outcomes.

Dr Gerald Prager is an Associate Professor of Medicine, Board Certified for Internal Medicine Board and Certified for Haematology and Medical Oncology. In 2009, he received his M.D. from the University of Vienna. Currently, Dr Prager is Director of the Colorectal Cancer Unit of the Department of Medical Oncology at the Medical University of Vienna. He is also a member of the ESMO 2014 Scientific Committee. The research interest of his lab focuses on (tumour-) angiogenesis via regulation of endothelial cell survival and migration by cell / extracellular-matrix interaction. Through his clinical training in haemato-oncology, he became a member of the sought-after group of medical researches. He achieved his expertise in international renowned labs at University of California, San Diego, the Norris Cancer Center, Los Angeles and the Department of Vascular Biology, Mississippi University for Women (MUW). His work is honoured by 19 international awards and resulted in publications in international highly renowned journals. Dr Prager’s young research group is embedded in an international cancer research campus associated with Medical University of Vienna (MUV).

Assoc. Prof. Gerald Prager has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Arcus, Astellas, AstraZeneca, Bayer, BMS, CECOG, Incyte, Lilly, MSD, Merck Serono, Pierre Fabre, Revolution Medicines, Roche, Servier, Takeda, Terumo

 

 

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center. Dr. Pant is recognised as an international expert in GI cancers with an emphasis on pancreatic and biliary cancers and Phase 1 trials.

 

Dr. Pant's research focuses on novel immunotherapeutic approaches and targeted therapies in GI cancers, including devising novel ways to target the KRAS mutation. He has been the lead/co-lead of several global practice-changing studies, including 'Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicenter, single-arm, phase 2b study'; 'Adagrasib in advanced solid tumors harboring a KRASG12C mutation' and 'Erdafitinib in patients with advanced solid tumors with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study'; amongst others. He has over 100 peer-reviewed publications and has published in high-impact journals, including The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He is frequently invited to present his research at national and international meetings. He collaborates on numerous grants, including R01 and SPORE grants funded by the National Institute of Health. Dr. Pant serves on the National Cancer Institute (NCI) Pancreas Task Force and the Pancreatic Cancer Action Network's (PanCan) Scientific and Medical Advisory Board. He also helped draft the American Society of Clinical Oncology (ASCO) Metastatic Pancreatic Cancer Guidelines, which provide evidence-based recommendations for physicians. He is also the editor of the book Pancreatic Cancer: Current Therapeutics and Future Directions (Publisher: Springer).

Prof. Shubham Pant has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting or advisory Role: Ipsen, Novartis, Nihon Medi-Physics Co, Daiichi Sankyo, Jazz Pharmaceuticals, AstraZeneca, Theriva Biosciences, Revolution Medicine, Arcus, BMS, Merck, Pfizer, EMD Serono, Bayer, Zymeworks, Sanofi.

Research funding (funding to institution): Incyte, Ipsen, Bristol-Myers Squibb, Boehringer Ingelheim, Arcus, Elicio, Pfizer, ImmunoMET, Immuneering, Jazz Therapeutics, Novartis, Revolution Medicine, AstraZeneca.

Consulting Entity: Oncomed LLC. Personally owned entity used for consulting activities. No commercial products.

Equity: Telperian

Programme summary
Take the e-learning now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.  

Meet the experts Independent IME approved

Other programmes of interest

eks
EKS / On-demand webinar
Oncology 
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand materials from an Experts Knowledge Share event

Experts
Dr Elizabeth Smyth, Prof. Aziz Zaanan, Prof. Markus Moehler
Endorsed by
  • download Downloadable
    Resources
  • clock 67 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Amgen.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
  • clock 10 MIN
  • calendar Jun 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025: BRAF-mutant and MSI-H/dMMR colorectal cancer (CRC)

Expert opinion on the latest practice-changing data

Experts
Prof. Dominik Modest, Dr Sara Lonardi
  • clock 5 MIN
  • calendar Jun 2025
  • Non-accredited Independent Medical Education

This content is intended for HCPs outside the UK & ROI only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
conference-update Conference update
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education